KIBRA identified as a tumor suppressor in osteosarcoma via Wnt/β-catenin inhibition
KIBRA overexpression suppresses osteosarcoma cell proliferation and migration while impairing DNA damage repair.
Asset / Drug
Drug and asset intelligence for KIBRA with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.